imaging studies have shown brain changes to occur during the course ofthe illness, but what do these changes mean? Similarly, functionalimaging studies have found a range of functional abnormalities inschizophrenia patients, but the specificity and stability of these changesare questionable. Indeed, neuroimaging so farhas failed to behelpful as adiagnostic orevenprognostic tool. Sowhat isnext?Nowit is claimedthatneuroimaging may be helpful in dissecting the functions of genesrelevant in psychiatric illness. And some studies using novel mathema-tical tools suggest that neuroimaging may, after all, be helpful inseparating disorders. This panel will review the usefulness of neuroima-ging in schizophreniaandreviewcritically its role in future schizophreniastudies with an emphasis on relating brain function to genes. Thefollowing questions will be addressed: Will neuroimaging help identifygenes relevant in schizophrenia?Will neuroimagingplaya role in furtherdefining schizophrenia?

doi:10.1016/j.schres.2010.02.023

PLENARY SESSION - ANTICIPATING DSM-V:NEW PARADIGMSCo-Chairpersons: John Kane, Wolfgang FleischhackerSunday, 11 April, 2010 - 8:30 am - 10:30 amDSM-V: NEW PARADIGMS AND OTHER CONTROVERSIES

William Carpenter1, Panelists: Alex Hofer2, Richard Keefe3, KimMueser4, Dieter Naber5, Eric Chen6

1University of Maryland School of Medicine Baltimore, MD, USA;2Medical University Innsbruck; 3Duke University Medical Center;4Dartmouth Psychiatric Research Center; 5University Medical CenterHamburg; 6University of Hongkong

DSM-V is scheduled for release in 2013. There will be extensiveefforts to harmonize with the next addition of ICD. The workgroup forPsychotic Disorders is considering modest changes in criteria forclassification and major changes affecting the following: a] subtypes ofschizophrenia; b] catatonia; and c] schizoaffective disorder. Two newparadigms may be added: a] the domains of pathology paradigm withdimensions representing critical aspects of psychopathology; and b] arisk syndrome chapter including a psychosis risk syndrome and mildcognitive impairment. The former is intended to address syndromeheterogeneity and focus assessment on pathologies requiring clinicalattention. The latter is hotly debated [see also SIRS program for debatesymposium]. The question of whether bipolar disorders should begrouped with psychotic disorders or mood disorders is being addressedand current status will be discussed. Field trials will begin in 2010. Plansaffecting psychotic disorders will be presented. Response from the SIRScommunity will provide the workgroup with important feedback.

doi:10.1016/j.schres.2010.02.025

NEWDIRECTONSFORANIMALMODELING INSCHIZOPHRENIA

Bita Moghaddam1, Panelists: Inna Gaisler-Salomon2, Patriot O′Donnell3, Akira Sawa4, Pierre Sokoloff5, Peter Uhlhaas61University of Pittsburgh; 2Haifa University; 3University of Maryland;4John Hopkins University School of Medicine; 5Pierre-Fabre ResearchInstitute; 6Max Plank Institute for Brain Research

Symposium 2MAKING CONNECTIONS: ABNORMAL WHITE MATTERDEVELOPMENT IN THE EARLY STAGES OF SCHIZOPHRENIAChairperson: Marc L. SealSunday, 11 April, 2010 - 3:30 pm - 5:30 pm

Overall Abstract: Neuropathological and neuroimaging studieshave consistently identified white matter abnormalities in schizo-phrenia, however, the development of this neuropathology and thefunctional implications of abnormal white matter in schizophreniaremain unclear. Significantly, recent studies suggest that whitematter abnormalities may be present in the early stages of theillness and even appear prior to illness onset. The aim of thissymposium is to review the current research involving in vivoassessment of white matter integrity in the early stages ofschizophrenia and to discuss these findings within the context ofhealthy neurodevelopment. The four presenters are internationalleaders in this field of research. Anthony James (Oxford) willpresent his work comparing shared and distinct white matterabnormalities between individuals with Early Onset Schizophrenia(EOS) and Early Onset Bipolar Disorder (EOB). Katie Karlsgodt(UCLA) will present an overview of her work on healthy whitematter development in adolescence and white matter abnormalitiesin individuals at high risk of developing psychosis. Marek Kubicki(Harvard Medical School) will present his work identifying fronto-temporal abnormalities in first episode schizophrenia. Gary Price(Institute of Neurology, London) will present an overview of his firstepisode schizophrenia tractography studies. Finally, Sophia Frangou(Institute of Psychiatry, London), who has published a recent reviewon this topic, will act as the Discussant.

doi:10.1016/j.schres.2010.02.026

COMPARISON OF GREY AND WHITE MATTER ANDNEUROPSYCHOMETRIC CHANGES IN EARLY-ONSETSCHIZOPHRENIA (EOS) AND EARLY-ONSET BIPOLARDISORDER WITH PSYCHOSIS (EOBP) VERSUS CONTROLS

Anthony JamesDepartment of Psychiatry, Univeristy of Oxford Oxford United Kingdom

Comparison of Grey and White Matter and NeuropsychometricChanges in Early-Onset Schizophrenia (EOS) and Early-OnsetBipolar Disorder with Psychosis (EOBP) versus Controls. AnthonyJames Recent genetic findings 1 have called into question thedichotomy between schizophrenia and bipolar disorder withpsychosis. To compare the neural networks underlying bothdisorders by examining white matter (WM), grey matter changes(GM) and cognitive function in an adolescent sample versus age-matched controls. A MRI and diffusion tensor imaging study of 43subjects with EOS, 15 with EOBP, and 36 controls. (DTI). In EOScases widespread WM changes were found in the major cortical,subcortical and cerebellar tracts with associated reduced GMdensity in the frontal and temporal lobes. By contrast, in EOBPdisorder WM changes were confined to the corpus callosum andGM changes to the bilateral cuneus/precuneus –visual processingareas, and the right crus of the cerebellum. Similar levels ofcognitive impairment were evident in EOS and EOBP, however, thepattern of correlation with WM and GM changes differed. Thepattern of WM and GM changes are suggestive of differing neuralnetwork abnormalities with an overlap in the corpus callosum. Thisadds some support for a distinction between EOS and EOBP in theearly stages of the neurodevelopment. 1. Craddock N. et al,Schizophrenia Research 2009, 35: 482-490.

doi:10.1016/j.schres.2010.02.027

Abstracts110